OMEGA - Journal of Death and Dying
February 1, 1980
William A. Richards, John Rhead, Stanislav Grof et al.
20 citations
Thirty cancer patients suffering from psychological distress participated in a pilot project of individual psychotherapy that offered – over a four week period of time – approximately twelve hours of conventional verbal interaction and a single intensive drug-assisted therapy session that employed dipropyltryptamine (DPT), a short-acting psychedelic drug. The efficacy of the total therapeutic...
Journal of Clinical Psychopharmacology
Nicole Ledwos, Joshua D. Rosenblat, Daniel M. Blumberger et al.
16 citations
There has been resurgence of interest in the therapeutic use of serotonergic ("classic") psychedelics in major depressive disorder (MDD) and end-of-life distress. This commentary offers a critical appraisal of current evidence for antidepressant effects of classic psychedelics from contemporary clinical trials and highlights pitfalls that should be addressed before clinical translation. A...
Kelley C O'Donnell, Michael Alpert, Lauren Okano et al.
preprint
Results from multiple recent studies support the use of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e., MDMA-Assisted Therapy) in the treatment of post-traumatic stress disorder (PTSD). In two Phase 3 trials, MDMA-Assisted Therapy comprised a short-term, intensive psychotherapy that included three sessions directly facilitated by MDMA (referred to as...
bioRxiv (Cold Spring Harbor Laboratory)
Hanna M. Tolle, Andrea I. Luppi, Timothy Lawn et al.
1 citation
preprint
Conventional antidepressants show moderate efficacy in treating major depressive disorder. Psychedelic-assisted therapy holds promise, yet individual responses vary, underscoring the need for predictive tools to guide treatment selection. Here, we present graphTRIP (graph-based Treatment Response Interpretability and Prediction) – a geometric deep learning architecture that enables three...
George Deane, Jonas Mago, Aikaterini Fotopoulou et al.
7 citations
preprint
This paper introduces the notion of adaptive narrative control, a conception of how subpersonal computational processes shape the contents of conscious experience to realize adaptive behavior. We unpack the implications of the theory for understanding the computational mechanisms underwriting psychopathology and improvements in subjective well-being associated with psychedelic therapy and...
Journal of Psychedelic Studies
October 30, 2026
Andy Letcher
Abstract: Background and aims: As contributions to this special issue attest, psychedelic integration is currently garnering much scholarly attention. However, given that most agree the focus on integration is recent, this paper asks why integration is being given such an emphasis now. What has changed in Western cultures of psychedelicisms, once preoccupied with just ‘set and setting’, that...
Journal of Psychedelic Studies
October 30, 2026
Victor Pablo Acero, Alan Kooi Davis
Abstract: Psychedelic-assisted therapy (PAT) may be approaching its own “Dodo Bird” moment: the appearance that multiple psychotherapeutic modalities “work” equally well, not because they are interchangeable, but because both symptom-focused outcome measures and, more fundamentally, the assumptions embedded in dominant RCT paradigms are ill-suited for probing the dynamic, relational, and...
Journal of Psychedelic Studies
October 30, 2026
Megan M. Druckrey
Abstract: The aim of this position paper is to explore and discuss the intersection of music therapy and psychedelic-assisted therapy, focusing on the safe and effective use of music during psilocybin treatment. Key points include a historical overview of psychedelic therapy, an examination of current research on the use of music in psychedelic therapy, and a rationale for why an...
Human Figurations
October 30, 2026
Michael Dunning, Jason Hughes, Hannah Farrimond et al.
In April 2026, US President Donald Trump signed an executive order fast-tracking access to psilocybin and ibogaine for the treatment of serious mental illness. This follows decades in which psychedelics had been vilified as a group of drugs entirely lacking in therapeutic potential, associated with counter-cultural groups such as hippies, and whose use was both criminalised and widely...
medRxiv
October 29, 2026
Ceyda Sayalı, Eli Weisman, Frederick Streeter Barrett
preprint
Background. Change in cognitive control is a candidate transdiagnostic mechanism of psychedelic therapy. One account predicts that, once acute effects resolve, psilocybin shifts control toward flexibility while sparing inhibition and working memory. A motivational account (PRISM) predicts that psilocybin increases the willingness to exert control rather than the ability to do so. We tested both...